A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma
Status:
NOT_YET_RECRUITING
Trial end date:
2027-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety of QLS4131 injection and to determine the recommended Phase 2 dose (RP2D) and to further evaluate the efficacy and safety of QLS4131 injection in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose.